01 Blood Culture Workflows Are Integrating With Laboratory Information Systems The need for faster, more accurate handling of time-sensitive blood culture results is increasing the integration of testing workflows with laboratory information systems. This transition connects blood culture orders, specimen details, results, contamination tracking, and reporting within digital laboratory workflows, with the CDC specifically recommending LIS data to calculate blood culture contamination and single-set rates on a monthly basis. The outcome is better result traceability, fewer manual steps, and stronger laboratory quality monitoring.
02 Contamination Reduction Is Becoming a Major Blood Culture Quality Priority The blood culture tests market analysis shows that the clinical consequences of false-positive cultures, including unnecessary antibiotic use and prolonged hospitalization, are increasing the focus on contamination prevention during blood culture collection. This transition is encouraging laboratories to monitor contamination rates, standardize collection procedures, and provide feedback to clinical teams, with the CDC noting that an overall contamination rate of 3% or lower is recommended and that rates around 1% are achievable with best practices. The outcome is more reliable blood culture results and reduced diagnostic and treatment errors.
01 Expansion of Hospital and Intensive Care Facilities and Increasing Incidence of Bloodstream Infections Drive Market Expansion of hospitals and intensive care facilities increases demand for blood culture tests because larger clinical capacity creates more testing requirements for patients with suspected infections. Intensive care units, for example, regularly evaluate critically ill patients with fever or suspected sepsis using blood cultures to identify bloodstream pathogens. This broader hospital infrastructure supports recurring procurement of blood culture bottles, testing systems, and related laboratory supplies.A higher incidence of bloodstream infections increases demand for blood culture tests as healthcare providers require laboratory confirmation of pathogens circulating in the blood. Patients with suspected sepsis, for example, may undergo blood culture testing to help identify the causative organism and guide antimicrobial treatment. This larger diagnostic workload increases testing volumes across hospitals and microbiology laboratories, supporting continued demand for blood culture products.
01 High Cost of Blood Culture Testing and Laboratory Maintenance and Challenges in Detecting Slow-Growing and Difficult-to-Culture Pathogens Restrain Market Expansion High costs of blood culture testing, automated systems, reagents, equipment, and laboratory maintenance can increase the financial burden on healthcare facilities. Higher operating and maintenance expenses can limit adoption in smaller hospitals and resource-constrained laboratories. Consequently, cost pressures can delay investments and restrict market expansion.Challenges in detecting slow-growing and difficult-to-culture pathogens can reduce the effectiveness and efficiency of conventional blood culture testing. Longer incubation periods and specialized testing requirements can delay diagnosis and increase the need for additional diagnostic methods. As a result, detection limitations can slow adoption and constrain market growth.
01 Blood Culture Tests for Antimicrobial Resistance Detection and Blood Culture Tests for Decentralized Diagnostic Settings Offer Growth Opportunities Hospitals, microbiology laboratories, and infectious disease centers are key customers for blood culture solutions that support rapid identification of antimicrobial-resistant bloodstream infections. Companies such as bioMérieux and BD can expand revenue through advanced culture systems, resistance-focused testing solutions, and specialized laboratory partnerships.Emergency departments, community hospitals, and decentralized healthcare facilities are key customers for blood culture testing solutions designed for faster and more accessible diagnostic workflows. Companies such as Thermo Fisher Scientific can generate revenue through compact testing systems, consumables, and diagnostic partnerships with healthcare providers, contributing to blood culture tests market growth.
01 Delayed Turnaround Time and Workflow Bottlenecks and Blood Culture Contamination and False-Positive Results Hinder Growth Blood culture testing requires incubation and multiple laboratory steps before pathogens can be identified and susceptibility results become available. Longer turnaround times can delay clinical decision-making and increase workflow pressure on laboratories, making it harder for healthcare providers to scale conventional blood culture testing efficiently.Blood culture contamination during specimen collection or handling can produce false-positive results that trigger additional testing, unnecessary antibiotic use, and increased hospital resource utilization. Higher contamination rates can reduce confidence in testing workflows and require laboratories to invest in improved collection practices and quality control, creating additional operational challenges for market expansion.
March 2026 Thermo Fisher Scientific completed the acquisition of Clario, expanding its digital clinical diagnostics and laboratory informatics capabilities to support microbiology laboratories and blood culture testing workflows.
October 2025 Thermo Fisher Scientific signed a definitive agreement to acquire Clario, strengthening its clinical trial and diagnostic data capabilities, including support for infectious disease testing and microbiology workflows used alongside blood culture diagnostics.
June 2025 Thermo Fisher Scientific signed a definitive agreement to acquire SomaLogic, expanding its life sciences and clinical diagnostics portfolio with advanced proteomics technologies that support infectious disease research and blood culture-based diagnostic applications.
May 2025 bioMérieux received U.S. FDA 510(k) clearance for VITEK® COMPACT PRO, expanding its microbiology portfolio with enhanced identification and antimicrobial susceptibility testing capabilities that complement blood culture workflows in clinical laboratories.